Navigation Links
Models developed from the PLCO may help identify at-risk patients for adverse smoking outcomes
Date:10/26/2012

Risk prediction models developed from an ancillary study of the Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCO) may be useful in the public health sector for identifying individuals who are at risk for adverse smoking outcomes, such as relapse among former smokers and continued smoking among current smokers, and those who may benefit from relapse prevention and smoking cessation interventions according to a study published October 26 in the Journal of the National Cancer Institute.

With a projected 226,160 new cases of lung cancer and 160,340 lung cancer deaths expected in the U.S. in 2012, researchers are looking at lung cancer screenings as a way to alter peoples' smoking behaviors. Although smoking abstinence is the most effective way to lower lung cancer mortality, both early detection and treatment of the disease may also lower mortality. Both the PLCO and the National Lung Screening Trial (NLST) have gathered data to determine whether screening can lower lung cancer mortality; however, the effects that screening has on smoking behavior is unknown.

To determine the effects of cancer screening on smoking behavior, Kathryn L. Taylor, Ph.D., of the Lombardi Comprehensive Cancer Center at Georgetown University, and colleagues, gathered data from participants who had completed a baseline questionnaire at PLCO trial enrollment and a supplemental questionnaire 4 years after enrollment, which assessed variables such as family history of cancer, comorbidity, and tobacco use. Multivariable logistic regression models were used to predict smoking status once the supplemental questionnaire was completed.

The researchers found that of the 31,694 former smokers on the baseline questionnaire, 1,042 had relapsed, and of the 6,807 current smokers, 4,439 had continued smoking on the supplemental questionnaire. Both relapse and continued smoking were statistically significantly linked with demographic, medical, and tobacco-related characteristics. "The relapse prediction model had excellent discrimination and calibration and suggested that relapse was more likely among longer-term smokers, recent quitters, smokers of light or ultra-light cigarettes, and pipe or cigar smokers," the researchers write, adding that the success of these models, "suggest important variables that should be considered in the development of effective intervention methods for long-term, heavily dependent smokers who are likely to be well represented in lung cancer-screening programs."


'/>"/>
Contact: Zachary Rathner
Zachary.Rathner@oup.com
301-841-1286
Journal of the National Cancer Institute
Source:Eurekalert

Related medicine news :

1. Genetically-engineered preclinical models predict pharmacodynamic response
2. TRPM7 protein key to breast cancer metastasis in animal models
3. Heterogeneous ER+ breast cancer models allow more accurate drug testing
4. Internists express support for new payment and delivery models as basis for replacing SGR
5. Super Models Line Up to Walk The Catwalk and Celebrate Vogue's Fashion Night Out in LA
6. Strategy developed to improve delivery of medicines to the brain
7. Multi-functional anti-inflammatory/anti-allergic developed by Hebrew University researcher
8. Heroes of Chemistry: Developed new drugs and technology to cut heating and cooling bills
9. Clinical trials start for stroke drug developed by Scripps Research, USC, and ZZ Biotech
10. New Facebook app to detect pedophiles and criminals developed by Ben-Gurion U. researchers
11. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and ... storing, shipping and disposal. The new version is a faster and a more ...
(Date:12/2/2016)... ... 2016 , ... Yisrayl Hawkins, at The House of Yahweh in Abilene, Texas, ... Bible Prophecy. Yisrayl says this generation, known as the Last Generation, started in 1934 ... details line up exactly with Bible Prophecy – a protected way for those who ...
(Date:12/2/2016)... ... December 02, 2016 , ... Date aired: November ... Type 2 Diabetes: The Owner’s Manual, http://realtimepressrelease.com/press-releases-tagged-with/daryl-wein , Sharon Kleyne, ... Water, Global Climate Change and Your Health radio program syndicated on Voice of ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Deloitte Wisconsin 75, an annual ranking and recognition of the largest closely held ... list, having ranked from 2008-2016. In addition, Standard Process was awarded the Talent ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... America held the largest share in the ECG ... population and demand for remote monitoring ECG devices. On the ... is expected to witness the highest growth rate during the ... (U.S.), Becton, Dickinson and Company (U.S.), Medtronic plc ( ... ) and Mindray Medical International Limited ( China ...
(Date:12/2/2016)... India , December 2, 2016 ... report "In Vitro Diagnostics/IVD Market by Product (Instruments, ... Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) ... global market is valued at USD 60.22 Billion ... at a CAGR of 5.5% during the forecast ...
(Date:12/2/2016)... 2, 2016 On Thursday, December ... excellence in research, development and innovation in the biopharmaceutical ... was held in the presence of Sergey Tsyb, Vice ... Russian Federation , Natalia Sanina, First Vice Chairman ... , Head of Roszdravnadzor, National Service of Control in ...
Breaking Medicine Technology: